Pharmacological Targets in Metabolic Diseases
Challenges and Opportunities
- 1st Edition - September 1, 2025
- Imprint: Academic Press
- Editor: Marcos Roberto de Oliveira
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 7 3 7 0 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 7 3 7 1 - 1
Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic develo… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.
- Covers the most prevalent metabolic diseases and disorders such as metabolic syndrome, diabetes mellitus (types I and II) and dyslipidemia, among others
- Includes chapters on the microbiome and environmental pollution as they relate to metabolic diseases and conditions
- Discusses cellular structures like the endoplasmic reticulum and mitochondria as pharmacological targets
Academic and corporate researchers in Pharmacy, Pharmacology, Biology, and Nutrition.
Subsection: Overview of metabolic diseases and disorders, biological alterations, and pharmacological targets
Part I Molecular level
1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview
2. Redox biology, metabolic disorders and therapeutic opportunities
3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity
4. NAPDH oxidase and diabetes mellitus: therapeutic strategies
5. Targeting reactive carbonyls in metabolic disorders
6. Antioxidant supplementation and metabolic disorders
7. Modulation of the immune system as a pharmacological target in metabolic diseases
Part II Subcellular and cellular levels
8. Modulation of mitochondrial physiology in the prevention and management of metabolic disorders
9. Targeting autophagy in metabolic diseases
10. Endoplasmic reticulum as a pharmacological target in metabolic diseases
II. Subsection: Organs as pharmacological targets in metabolic diseases and disorders
11. The gut-brain axis as a pharmacological target in metabolic diseases
12. Cardiomyopathy in metabolic diseases: pharmacological strategies
13. The cardio-renal-metabolic connection as a pharmacological target
14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases
15. Diabetic kidney disease: treatment and challenges
16. Fatty liver disease: a therapeutical approach
17. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Part III Subsection: Diabetes mellitus
18. Pharmacological management of diabetes mellitus complications
Part IV Subsection: Obesity
19. Pharmacological targets in obesity
20. Diet, obesity, and methylglyoxal: therapeutic opportunities
21. Obesity-related dyslipidemia: pharmacological targets and opportunities
Part V Subsection: Metabolic syndrome
22. Metabolic syndrome: pharmacological strategies and challenges
23. Pharmacological targets in metabolic syndrome-related dyslipidemia
24. Therapeutic intervention in metabolic syndrome: present status and perspectives
Part VI Subsection: Inborn errors of metabolism
25. Fatty acid oxidation disorders: a pharmacological approach
26. Pharmacological treatment of phenylketonuria
27. Pharmacological targets in inborn errors of metabolism in adult patients
Part VII Subsection: Natural molecules and metabolic diseases and disorders
28. Polyphenols and obesity: molecular targets and therapeutic potential
29. Plant molecules and diabetes mellitus: prevention and management
30. Molecular targets in dyslipidemia: therapeutic potential of plant molecules
31. Polyphenols and modulation of cholesterol metabolism
32. Polyphenols and the control of immunometabolism as a pharmacological target
Part VIII Subsection: Microbiota and metabolic diseases and disorders
33. Microbiota, metabolic disorders and pharmacological opportunities
34. Plant extracts/molecules in obesity and the gut microbiota
35. Microbiome/microbiota and diabetes mellitus: pharmacological opportunities and challenges
36. Microbiome/microbiota and fatty liver disease: potential candidate for therapeutic intervention
Part IX Subsection: Aging
37. Aging, metabolic disorders and the mitochondria: pharmacological opportunities
Part X Subsection: Nanotechnology and metabolic diseases and disorders
38. Nanotechnology-related strategies for the prevention of metabolic syndrome
Part XI Subsection: Metabolic diseases and disorders and the environment
39. Environmental pollution and metabolic diseases: a pharmacological challenge
Part XII Subsection: Diagnostic of metabolic diseases and disorders
40. Diagnostic techniques in metabolic diseases and disorders
Part I Molecular level
1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview
2. Redox biology, metabolic disorders and therapeutic opportunities
3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity
4. NAPDH oxidase and diabetes mellitus: therapeutic strategies
5. Targeting reactive carbonyls in metabolic disorders
6. Antioxidant supplementation and metabolic disorders
7. Modulation of the immune system as a pharmacological target in metabolic diseases
Part II Subcellular and cellular levels
8. Modulation of mitochondrial physiology in the prevention and management of metabolic disorders
9. Targeting autophagy in metabolic diseases
10. Endoplasmic reticulum as a pharmacological target in metabolic diseases
II. Subsection: Organs as pharmacological targets in metabolic diseases and disorders
11. The gut-brain axis as a pharmacological target in metabolic diseases
12. Cardiomyopathy in metabolic diseases: pharmacological strategies
13. The cardio-renal-metabolic connection as a pharmacological target
14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases
15. Diabetic kidney disease: treatment and challenges
16. Fatty liver disease: a therapeutical approach
17. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Part III Subsection: Diabetes mellitus
18. Pharmacological management of diabetes mellitus complications
Part IV Subsection: Obesity
19. Pharmacological targets in obesity
20. Diet, obesity, and methylglyoxal: therapeutic opportunities
21. Obesity-related dyslipidemia: pharmacological targets and opportunities
Part V Subsection: Metabolic syndrome
22. Metabolic syndrome: pharmacological strategies and challenges
23. Pharmacological targets in metabolic syndrome-related dyslipidemia
24. Therapeutic intervention in metabolic syndrome: present status and perspectives
Part VI Subsection: Inborn errors of metabolism
25. Fatty acid oxidation disorders: a pharmacological approach
26. Pharmacological treatment of phenylketonuria
27. Pharmacological targets in inborn errors of metabolism in adult patients
Part VII Subsection: Natural molecules and metabolic diseases and disorders
28. Polyphenols and obesity: molecular targets and therapeutic potential
29. Plant molecules and diabetes mellitus: prevention and management
30. Molecular targets in dyslipidemia: therapeutic potential of plant molecules
31. Polyphenols and modulation of cholesterol metabolism
32. Polyphenols and the control of immunometabolism as a pharmacological target
Part VIII Subsection: Microbiota and metabolic diseases and disorders
33. Microbiota, metabolic disorders and pharmacological opportunities
34. Plant extracts/molecules in obesity and the gut microbiota
35. Microbiome/microbiota and diabetes mellitus: pharmacological opportunities and challenges
36. Microbiome/microbiota and fatty liver disease: potential candidate for therapeutic intervention
Part IX Subsection: Aging
37. Aging, metabolic disorders and the mitochondria: pharmacological opportunities
Part X Subsection: Nanotechnology and metabolic diseases and disorders
38. Nanotechnology-related strategies for the prevention of metabolic syndrome
Part XI Subsection: Metabolic diseases and disorders and the environment
39. Environmental pollution and metabolic diseases: a pharmacological challenge
Part XII Subsection: Diagnostic of metabolic diseases and disorders
40. Diagnostic techniques in metabolic diseases and disorders
- Edition: 1
- Published: September 1, 2025
- No. of pages (Paperback): 600
- No. of pages (eBook): 600
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780443273704
- eBook ISBN: 9780443273711
MO
Marcos Roberto de Oliveira
Marcos Roberto de Oliveira, PhD earned his bachelor’s degree in Biological Sciences at Federal University of Rio Grande do Sul (UFRGS) in 2005, followed by a master’s and a Ph.D. in Biochemistry from the same institution. He is currently a professor and coordinates research at UFRGS. His research focuses on the neuroprotection mediated by natural molecules and involves studies on mitochondrial physiology, redox biology, bioenergetics, and inflammation in both in vitro and in vivo experimental models.
Affiliations and expertise
Professor, Department of Biochemistry, Federal University of Rio Grande do Sul, Universidade Federal do Rio Grande do Sul (UFRGS), Instituto de Ciências Básicas da Saude (ICBS), Departamento de Bioquímica, Rua Ramiro Barcelos, Brazil